Portland, OR, March 05, 2020 (GLOBE NEWSWIRE) -- The Antifibrinolytic Drugs Market size was estimated at $13.59 billion in 2018 and is expected to hit at $19.33 billion by 2026, registering a CAGR of 4.5% from 2019 to 2026. The report provides a detailed analysis of the market size & estimations, top investment pockets, top winning strategies, drivers & opportunities, competitive scenario, and wavering market trends.
Increase in road accidents and improvement in surgical procedures drive the growth of the global antifibrinolytic drugs market. On the other hand, high cost of these drugs impedes the growth to some extent. However, untapped potential in developing countries is anticipated to pave the way for several opportunities in the near future.
Request Sample Report at https://www.alliedmarketresearch.com/request-sample/6279
The gynecology segment to lead the trail by 2026-
Based on indication, the gynecology segment accounted for nearly one-third of the total market share in 2018, and is expected to rule the roost throughout the forecast period. The surgeries segment, on the other hand, is projected to grow at the fastest CAGR of 5.9% from 2019 to 2026. The other segments discussed in the report include hereditary angioedema, and fibrinolytic response testing.
The hospitals and clinics segment to retain its dominance in terms of revenue-
Based on end-user, the hospitals and clinics segment contributed to nearly half of the total market revenue in 2018 and is anticipated to dominate during the study period. Simultaneously, the trauma centers segment is expected to manifest the fastest CAGR of 5.1% by 2026. The segment of ambulatory surgical centers is also analyzed in the report.
North America garnered the highest share in 2018-
Based on geography, North America garnered a major share in 2018, holding more than two-fifths of the total market. At the same time, the Asia-Pacific region would grow at the fastest CAGR of 6.1% during 2019–2026. The other two regions assessed in the market report take in Europe and LAMEA.
For Purchase Enquiry at https://www.alliedmarketresearch.com/purchase-enquiry/6279
Leading market players-
The key market players analyzed in the global antifibrinolytic drugs market include Xanodyne Pharmaceuticals, Akorn, Takeda, Amerigen Pharms Ltd, Mylan, Acic Fine Chems, Pfizer (GenMed), Sanofi, Zydus Cadila, and Aurobindo Pharma Ltd. They have incorporated a number of strategies including partnership, expansion, collaboration, joint ventures, and others to heighten their stand in the industry.
Avenue Basic Plan | Library Access | 1 Year Subscription
Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.
Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter
Get more information: https://www.alliedmarketresearch.com/library-access
Similar Reports:
Fall Management Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
Trauma Products Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
Neurology devices Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
Immunosuppressants Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
Hybrid Operating Room Market: Global Opportunity Analysis and Industry Forecast, 2019–2026
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains.